Creative Biolabs CAR-T Blog

Menu

Skip to content
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News

Category Archives: Chimeric Antigen Receptor Research

04Jan/18
gene-engineered T cell immunotherapy of cancer

Literature Reading: Driving Gene-engineered T Cell Immunotherapy of Cancer

January 4, 2018Chimeric Antigen Receptor ResearchCAR-T, CD19-targeted CARs, Chimeric antigen receptor (CAR), Global CAR-T clinical trial review, TCR engineered T cellbiocart

This is a review article published on Cell Research (2017) 27: 38-58 by Laura A Johnson and Carl H June. Dr. Carl H. June is the director of translational research at the Abramson Cancer CenterRead More…

22Dec/17

The Latest Developments in CAR-T Research

December 22, 2017Chimeric Antigen Receptor Research, NewsCAR-T, CAR-T immunotherapy, CD19-targeted CAR immunotherapy, CD22-targeted CAR T cells, Chimeric Antigen Receptor Tbiocart

CAR-T, Chimeric Antigen Receptor T Cell Immunotherapy, is a new cell therapy that has been developed for many years but has only been improved in recent years. Considered as one of the most promisingRead More…

24Nov/17

Latest Research Results on CAR-T Therapy reveal a possible reason of CAR-T neurotoxicity

November 24, 2017Chimeric Antigen Receptor Research, NewsCAR-T, CAR-T cell expansion, CAR-T therapies, CAR-T trialbiocart

There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…

22Nov/17

Actemra/RoActemra® Is Approved by FDA for the Treatment of Cytokine Release Syndrome Caused by CAR-T Therapy

November 22, 2017Chimeric Antigen Receptor ResearchCAR-Tbiocart

Actemra/RoActemra® is the first FDA approved drug for treatment of serious or fatal cytokine release syndrome (CRS) caused by CAR-T therapy; CAR-T cell therapy is an immunotherapy used to treat certain typesRead More…

22Nov/17

CAR-T for Autoimmune Disease and Blastoma Therapy

November 22, 2017Chimeric Antigen Receptor ResearchCAR-Tbiocart

CAR-T for Autoimmune Disease An autoimmune disease is a pathological condition resulting from an abnormal immune response to tissues that can exist in the body, affecting up to 50 million Americans in termsRead More…

22Nov/17

The Application of CAR-T in Disease Treatment

November 22, 2017Chimeric Antigen Receptor Research, TCR ResearchCAR-T, TCRbiocart

Chimeric antigen receptor (CAR) modified T cells (CAR-T) as a new field of adoptive immune cell therapy has become a hot spot in recent research. In 1989, Israeli scholar Gross et al.Read More…

22Nov/17

Carl June Published His Latest Paper: The Results of CAR-T Therapy Human Trials on the Treatment of Solid Tumors Shows Two Hurdles Still Need to Be Overcome!

November 22, 2017Chimeric Antigen Receptor Research, NewsCAR-T, TCRbiocart

In this month, FDA oncologic Drugs Advisory Committee agreed to the approval of Novartis’s CAR-T CTL019 therapy on a vote of 10:0 for the treatment of relapsed or refractory children and youngRead More…

22Nov/17

Is Bio-distribution Study Necessary for CAR-T Therapy?

November 22, 2017Chimeric Antigen Receptor ResearchCAR-T, TCRbiocart

Biological therapy includes a variety of models, such as immunotherapy, gene therapy, regulation of angiogenesis therapy, small molecule targeting drugs and stem cells and tissue engineering regenerative medicine. Among them, cancer immunotherapyRead More…

22Nov/17

Revelation! CAR-T Has Its “Eyes” on Solid Tumor and the Treatment of That Would Be Possible

November 22, 2017Chimeric Antigen Receptor ResearchCAR-T, TCRbiocart

Immunotherapy has become a new hope against cancer. CAR-T cell therapy is achieved by using genetic engineering method to express chimeric antigen receptors on T cells obtained from donner patients. These chimeric antigenRead More…

22Nov/17

Comparison between CAR-T and TCR-T

November 22, 2017Chimeric Antigen Receptor Research, TCR ResearchCAR-T, TCRbiocart

As a matter of fact, tumor immunotherapy is divided into two categories. One is to show immune cells the tumor features, then direct them to locate and kill tumor cells. And anotherRead More…

Posts navigation

  • « Previous
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next »

Categories

  • Cancer Immunotherapy
  • Chimeric Antigen Receptor Research
  • COVID-19
  • Events
  • HLA Typing
  • News
  • Oncolytic Virus Therapy Research
  • TCR Research

Recent Posts

  • CAR-T Cells Targeting PSCA Show Promise in Treating Metastatic Castration-Resistant Prostate Cancer
  • Advancements and Challenges in CAR-Macrophage Therapy: A New Frontier in Cancer Immunotherapy
  • NK Cell Surveillance Limits T Cell Responses: Implications for Cancer Immunotherapy
  • High-throughput Discovery of Tumor-Reactive T Cell Receptors: Advancing Personalized Cellular Immunotherapy
  • Overcoming Resistance: Enhancing CAR-T Therapy for AML with TP53 Mutations

Archives

Contact Us

USA - UK

Copyright © Creative Biolabs CAR-T Blog
Powered by WordPress , Theme i-max by TemplatesNext.
MENU
  • Chimeric Antigen Receptor Research
  • TCR Research
  • Oncolytic Virus Therapy Research
  • News